CTOR: citiusonc.com Price/Earnings to Growth Multiple
Strong physician confidence positions Citius Oncology, Inc. (CTOR) as a promising niche leader. This chart on GURU.Markets shows that the normalized PEG ratio confirms this potential, with the parameter reaching 0.00. Growth is driven by the expansion of LYMPHIR into US hospitals, the establishment of supply chains for lymphoma therapies, and the development of a pipeline of targeted drugs for rare forms of cancer.
Analytical breakdowns for Citius Oncology, Inc. (CTOR)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Citius Oncology, Inc.|CTOR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio citiusonc.com|CTOR - Company Aggregate Debts|Debts to Net Assets Citius Oncology, Inc|CTOR - Company Long-Term Liabilities|Amount of Current Liabilities Citius Oncology|Interim Coverage Ratio citiusonc.com
- company profitability and valuation multiples indicators:
CTOR - Net Income|Projected Future Earnings Citius Oncology, Inc.|CTOR - Price to Earnings Ratio|Market Cap to Projected Earnings Citius Oncology Inc|CTOR - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Citius Oncology, Inc|CTOR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Citius Oncology|CTOR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months citiusonc.com|CTOR - Earnings growth in current year|Expected earnings per share growth for next year Citius Oncology, Inc.
General company analysis:CTOR, Citius Oncology Inc.
Citius Oncology, Inc. (CTOR) is developing innovative immunotherapy for bladder cancer, where future insurance reimbursements determine the business's scaling potential. This PEG ratio compares the stock's market value with its earnings growth rate, making it possible to identify undervalued assets. Values below one on this chart signal high investment attractiveness for the issuer relative to its expansion within the oncology sector.
Who Citius Oncology, Inc. competes with
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple DCTH|Price/Earnings to Growth Multiple ymabs.com YMAB|PEG Multiple AURA (Aura Biosciences)|Growth-Adjusted Market Cap to Net Income Candel Therapeutics Inc. (CADL)|ARAY: Price/Earnings to Growth Multiple|SELLAS Life Sciences - Company Value to Earnings Growth Ratio|ACTU: PEG Multiple|HURA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple TARA|PEG Multiple Fate Therapeutics Inc|Price/Earnings to Growth Ratio Aadi Bioscience Inc (WHWK)|Growth-Adjusted Market Cap to Net Income tscan.com|Champions Oncology, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XBIT|CVM - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate OS Therapies Inc.|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ARTV|ANL (Adlai Nortye Ltd) - PEG Multiple|Price/Earnings to Growth Multiple verupharma.com (VERU)|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|XLO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Renovaro RENB|Mural Oncology PLC - Price/Earnings to Growth Ratio|KAPA - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate OnKure Therapeutics Inc|GDTC: PEG Multiple|Price to Net Income Growth Ratio Curis CRIS|Price/Earnings to Growth Multiple APLM|Price to Earnings Adjusted for Growth Rate Tharimmune Corporation THAR|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc)|GNPX (genprex.com) - Growth-Adjusted Payback Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Sunshine Biopharma Inc. (SBFM)|XBIO - Price/Earnings to Growth Ratio|SLRX (Salarius Pharma) - Growth-Adjusted P/E Ratio|PPBT: PEG Multiple|Price/Earnings to Growth Multiple American Oncology Network, Inc.|Price/Earnings to Growth Multiple BGNE|Checkpoint Therapeutics Inc. (CKPT) - Growth-Adjusted Market Cap to Net Income|PEG Multiple ELEV|Price/Earnings to Growth Multiple icadmed.com ICAD|Ikena Oncology - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio NTBL (notablelabs.com)|VIRX - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate MorphoSys Inc|NAYA Bio (NAYA) - Price/Earnings to Growth Ratio|Ascentage - Growth-Adjusted Payback Ratio
